Search
elinzanetant
Investigational
Indications:
- vasomotor symptoms of menopause
- improves sleep disturbances & menopause-related quality of life
Dosage:
- 120 mg PO QD
Adverse effects:
- headache & fatigue most common (7-9% vs 2.5-2.6% for placebo)
- no serious adverse effect in clinical trial [1]
Mechanism of action:
- selective neurokinin-1,3 receptor antagonist
General
endocrine agent
receptor antagonist
References
- Pinkerton JV, Simon JA, Joffe H et al
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause.
OASIS 1 and 2 Randomized Clinical Trials.
JAMA. Published online August 22, 2024.
PMID: 39172446
https://jamanetwork.com/journals/jama/fullarticle/2822766